832735-54-3

Usage

Uses

Used in Pharmaceutical Research:
2-Benzyloxypyridine-5-boronic acid, pinacol ester is used as a reagent in Suzuki-Miyaura coupling reactions for the formation of carbon-carbon bonds in the synthesis of complex organic molecules. Its high reactivity and selectivity make it an important tool in the development of new pharmaceutical compounds.
Used in Agrochemical Research:
In agrochemical research, 2-Benzyloxypyridine-5-boronic acid, pinacol ester serves as a key reagent in Suzuki-Miyaura coupling reactions, facilitating the construction of complex organic molecules for the development of new agrochemicals.
Used in Organic Synthesis:
2-Benzyloxypyridine-5-boronic acid, pinacol ester is utilized as a versatile building block in organic synthesis, thanks to its enhanced stability and solubility provided by the pinacol ester group. This allows for the efficient synthesis of a wide range of organic compounds for various applications.

InChI:InChI=1/C18H22BNO3/c1-17(2)18(3,4)23-19(22-17)15-10-11-16(20-12-15)21-13-14-8-6-5-7-9-14/h5-12H,13H2,1-4H3

Upstream product

• 766-11-0 5-bromo-2-fluoropyridine 
• 624-28-2 2,5-dibromopyridine 
• 83664-33-9 2-(benzyloxy)-5-bromopyridine 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1257425-38-9 (6S)-6-({2-[6-(benzyloxy)-3-pyridinyl]benzyl}oxy)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 
• 1393479-23-6 2-(benzyloxy)-5-(2,2,3,3,3-pentafluoropropyl)pyridine 
• 1584686-28-1 tert-butyl 6-(benzyloxy)nicotinate 
• 1620291-95-3 N-((5-((2-(6-(benzyloxy)pyridin-3-yl)phenoxy)methyl)-4,5-dihydroisoxazol-3-yl)methyl)imidazo[1,2-a]pyridine-6-carboxamide 
• 1620291-96-4 N-((5-((2-(6-hydroxypyridin-3-yl)phenoxy)methyl)-4,5-dihydroisoxazol-3-yl)methyl)imidazol[1,2-a]pyridine-6-carboxamide 
• 1620294-33-8 tert-butyl ((5-((2-(6-(benzyloxy)pyridin-3-yl)phenoxy)methyl)-4,5-dihydroisoxazol-3-yl)methyl)carbamate 
• 1181377-33-2 tert-butyl 4-(6-(benzyloxy)pyridin-3-yl)-3-nitrophenylcarbamate 

Relevant academic research and scientific papers

ION CHANNEL MODULATORS

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

Imidazopyrazine compound, and preparation method and application thereof

The invention belongs to the technical field of medicines and relates to an imidazopyrazine compound, and a preparation method and an application thereof. Specifically, the invention relates to a compound with a structure shown in a formula (I) defined in the specification, a pharmaceutically acceptable salt of the compound, a stereisomer of the compound or a prodrug of the compound, and an application of the compound, the pharmaceutically acceptable salt of the compound, the stereisomer of the compound or the prodrug of the compound to the preparation of drugs. The drugs are used for preventing and/or treating diseases and/or symptoms, related to the over-activity of Bruton's tyrosine kinases, of subjects. The invention furthermore relates to an application of the compound, pharmaceutically acceptable salts of the compound, the stereisomer of the compound or the prodrug of the compound to the preparation of preparations. The preparations are used for reducing or inhibiting the activity of the Bruton's tyrosine kinases in cells.

PYRROLIDINONE DERIVATIVES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS

The present invention relates to pyrrolidinone derivatives of formula (I). The pyrrolidinone derivatives of formula (I) are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of pyrrolidinone derivatives as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.